Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis (SUPPORT)

This study has been withdrawn prior to enrollment.
(Study will not be initiated as planned.)
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT01327664
First received: February 24, 2011
Last updated: December 5, 2013
Last verified: December 2013

February 24, 2011
December 5, 2013
March 2011
May 2014   (final data collection date for primary outcome measure)
  • Participants with adverse events as a measure of safety and tolerability [ Time Frame: up to 36 months ] [ Designated as safety issue: Yes ]
  • Proportion of patients achieving the criteria for clinically inactive posterior segment uveitis [ Time Frame: up to 36 months ] [ Designated as safety issue: No ]
  • Mean time to achieve the criteria for clinically inactive posterior segment uveitis [ Time Frame: up to 36 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01327664 on ClinicalTrials.gov Archive Site
  • Proportion of patients experiencing clinically active posterior segment uveitis in patients discontinuing AIN457 treatment [ Time Frame: up to 36 months ] [ Designated as safety issue: No ]
  • Time to recurrence of clinically active posterior segment uveitis after discontinuation of AIN457 treatment [ Time Frame: up to 36 months ] [ Designated as safety issue: No ]
  • Time to resolution of a recurrence of clinically active posterior segment uveitis in patients discontinuing AIN457 and treated only with the reinitiation of AIN457 [ Time Frame: up to 36 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis

This study will provide patients who have completed the AIN457 Phase II and Phase III clinical trials in non-infectious uveitis continued access to treatment with AIN457 while collecting safety data and information on long term clinical use of treatment with AIN457.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Uveitis
Biological: AIN457
Experimental: AIN457 300mg s.c every 2 weeks
Intervention: Biological: AIN457
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must be able to understand and communicate with the investigator and comply with the requirements for the study and must give a written, signed, and dated informed consent before any study assessment is performed
  • Patient is currently enrolled in CAIN457A2208 or has completed the core and extension study treatment periods in the ongoing AIN457 phase III clinical trial Studies (e.g., CAIN457C2301 and CAIN457C2301E1)
  • Willingness to discontinue AIN457 or be weaned from standard of care immunosuppressive therapy if recommended by the study investigator

Exclusion Criteria:

  • Need for treatment with ocular procedures or systemic medications prohibited in this study including an alkylating agent or another biologic therapy other than AIN457
  • Pregnant or nursing (lactating) women
  • Women of childbearing potential unwilling to use protocol defined acceptable methods of contraception throughout the study and for 16 weeks after study drug discontinuation

Other protocol-defined inclusion/exclusion criteria may apply

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01327664
CAIN457C2399, 2010-021239-15
Not Provided
External Affairs, Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP